Lingyu Zhang

A PB@PAA-CaO ₂ @PDA platform integrating calcium release, drug loading, and photothermal conversion was facilely constructed, enabling efficient antitumor efficacy through synergistic calcium overload/photothermal/chemotherapy.

In response to the different desolvation states of hydrated Zn²⁺, high-entropy alloy exhibits significant catalytic effects on the removal of each coordinated water molecule, resulting in efficient graded and completed desolvation of hydrated Zn²⁺.

High entropy sulfide (HES) exhibits high catalytic activity and structural stability due to the synergistic effect and high entropy effect of various metals. However, the conventional approach for synthesizing HES typically necessitates elevated temperatures to ensure homogeneous blending of multiple elements, which directly results in nanoparticle agglomeration and unsatisfactory electrochemical performance. Herein, we propose the HES as a novel separator modifier for lithium–sulfur batteries, which overcomes the limited adsorption-catalytic synergy of conventional single metal sulfides. Ultrafine FeCoNiCrMnS₂ nanospheres (HES NSs) are synthesized via a facile template method, where the multi-metal synergy enables simultaneous suppression of polysulfide shuttling and acceleration of redox kinetics. The ultrafine HES nanocrystals can expose a sufficient number of active sites, which serve as an efficient LiPSs barrier to inhibit side reactions and as an additional collector to enhance the polysulfide redox reaction. As a result, the battery employing HES//PP separators exhibits outstanding cycle stability (906.8 mA h g⁻¹ at 1.0 C after 1000 cycles). This study not only showcases the potential application of HES as a separator modifier for Li–S batteries but also provides novel insights into exploring other high-entropy materials.

Self-supporting layers containing high-entropy materials (HEMs) with adsorption–catalytic-conversion integrated functions were designed and synthesized for the first time for separator modification of Zn–I ₂ batteries.

Portal vein tumor thrombus (PVTT) is a poor prognostic factor for hepatocellular carcinoma (HCC) patients, highlighting the need for an oral drug delivery system that combines convenience, simplicity, biosafety, and improved patient compliance. Leveraging the unique anatomy of the portal vein and insights from single-cell RNA sequencing of the PVTT tumor microenvironment, we developed oral pellets using CaCO3@PDA nanoparticles (NPs) encapsulating both doxorubicin hydrochloride and low molecular weight heparin. These NPs target the tumor thrombus microenvironment, aiming to break down the thrombus barrier and turn the challenge of portal vein blockage into an advantage by enhancing drug delivery efficiency through oral administration. The NPs-based oral delivery system achieved excellent antitumor effects with minimal side effects, demonstrating a promising strategy for managing PVTT in advanced HCC and addressing tumor types associated with vascular invasion and hypercoagulability.